Active pharmaceutical ingredient (API) Global Market – Forecast To 2027

Publishing Date : March, 2021
Report Code : HCPH 0100
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

Active Pharmaceutical Ingredients (APIs) are active substances in a drug intended to achieve pharmacological activity which is having a direct effect on disease treatment. APIs are synthesized by chemical synthesis, fermentation, biotechnological methods or enhanced from the natural source. According to IQ4I analysis, the global Active Pharmaceutical Ingredient market is expected to grow at a high single digit CAGR from 2020 to 2027 to reach $364,169.4 million by 2027. Adoption of biologics in disease management and increasing regulatory approvals in the past year, increasing scope of HPAPI market, patent expiration of major drugs, increasing trend of outsourcing, and increase in geriatric population are some of the factors driving the market growth. The global API market is mainly segmented by synthesis, by business type, by application, and by geography.

The global API market based on synthesis is further divided into synthetic API, Biotech API, and HPAPI. By synthesis, the synthetic API held the major share in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. The major factors driving the synthetic chemical API market are patent expiration of synthetic (small molecule drugs), an increasing number of small molecules in clinical trials, increasing outsourcing by the pharmaceutical companies, CMOs investments to expand manufacturing facilities, rise in the incidence of chronic and age-related diseases, rapid growth in the oncology market, technological advancement like cryogenic and continuous flow manufacturing. Biotech API accounted for the share of xx% in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. Increased investment in R&D by pharmaceutical companies for developing biologic drugs, adoption of biological therapies in disease management, increasing outsourcing, increasing biologics approvals in the past year, increasing chronic and autoimmune illnesses, increasing number of branded drugs going off-patent creating a scope for biosimilars, requirement of novel biologics therapeutics for rare diseases, increasing demand for antibody conjugates, bi or multispecific monoclonal antibodies, and vaccines to contain novel coronavirus infections are few factors driving the biotech API market.

Biotech API is further segmented into monoclonal antibodies, recombinant proteins, vaccines, and others (stem cell therapy and gene therapy). Monoclonal antibodies accounted for the largest share in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. The development of next-generation antibodies such as antibody-drug conjugates and rising venture capital investments and applications of monoclonal antibodies are the factors booming monoclonal antibodies market growth. The vaccine segment is forecasted to grow at a low teen CAGR from 2020 to 2027 owing to the worldwide demand for novel vaccines to treat the coronavirus diseases which emerged as a global pandemic.

Based on the customer base, the global biotech API is further segmented into biologics and biosimilars. Biologics accounted for the largest share in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. The Biologics market is driven globally due to the adoption of biological therapies in disease management, increasing biologics approvals in the past year, increasing chronic and autoimmune illnesses, and increasing the elderly population. Biosimilars accounted for the share of xx% in 2020 and is expected to grow at an exponential CAGR from 2020 to 2027 owing to patent expiry of biological drugs, low cost compared to biologics, increase in chronic diseases, growing geriatric population, and demand for quality healthcare.

Based on the customer base, the global synthetic API is further divided into branded API and generic API. The Branded API accounted for the largest share in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027. The Generic API is expected to grow at a high single digit CAGR from 2020 to 2027, due to the patent expiry of blockbuster drugs, rising healthcare expenses, and shift towards generic medicines led by government initiatives.

By business type, the global API market is divided into captive API and merchant API. The Captive market held the major share in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. The captive API is further divided into branded captive API and generic captive API. The branded captive API accounted for the largest share in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027 owing to patent protection of blockbuster drugs. The Merchant API market is further divided into branded merchant API and generic merchant API. The Generic merchant API accounted for the largest share in 2020 and is expected to grow at a low teen CAGR from 2020 to 2027. Increasing outsourcing, advanced manufacturing facilities, lack of in-house manufacturing capability, high capital investment, and cost of API manufacturing are some of the factors driving the Merchant API market.

By therapeutic applications, the global API market is segmented into infectious diseases, oncology, cardiovascular disorders, central nervous system, pulmonary disorder, gastrointestinal disorder, endocrine disorders, metabolic disorders, genito-urinary disorders, musculoskeletal disorders, and others such as others such as ophthalmology, autoimmune diseases, ENT, dental, dermatology, and pain management. In the application segment, infectious disease accounted for the largest share in 2020 because of the global-wide rapid spread of COVID-19 and increased incidence of other infectious diseases such as tuberculosis, HIV, pneumonia, influenza, hepatitis, and others. The oncology division is expected to grow at a double digit CAGR from 2020 to 2027 driven mainly by the rising incidence of cancer cases, lifestyle changes, increasing geriatric population, high demand for anti-cancer drugs. Currently, there is a trend towards precision medicine which further boosts the global oncology API market growth.

The global API market by therapeutic application is segmented into synthetic API application, biotech API application, and HPAPI application market. In synthetic API application, infectious disease accounted for the largest share in 2020 and oncology is expected to grow at a high single digit CAGR from 2020 to 2027. Under biotech API and HPAPI, the oncology segmented contributed for the largest share of xx% and xx% in 2020 respectively, and is forecasted to grow at a high single digit CAGR of xx% and xx% from 2020 to 2027.

The active pharmaceutical Ingredients market by region is segmented as North America, Europe, Asia-Pacific, and the Rest of the world (ROW). By geography, North America held the largest share in 2020 due to patent expiration of the major drugs, rising demand for biotech APIs, market entry of biosimilars, increasing scope of highly potent drugs, and increase in the prevalence of chronic diseases such as cancer, cardiac disease, diseases associated with central nervous system, and musculoskeletal disorder coupled with high healthcare expenditure. Asia-Pacific is the fastest-growing region with a high single digit CAGR from 2020 to 2027 owing to low labor cost, abundance availability of raw materials, infrastructure facility, rise in generic drug demand, increased production capabilities, the presence of a large number of domestic and international players, and concentration of CMO companies.

Some of the key players of Active pharmaceutical Ingredient (API) market are Lonza Group (Switzerland), Boehringer Ingelheim GmbH (Germany), Teva Pharmaceutical Industries Ltd (Israel), Sanofi S.A. (France), Thermo Fisher Sceintific Inc. (Patheon N.V, U.S), Divis Laboratories (India), Olon S.p.A (Italy), Pfizer Inc. (U.S.), Permira funds (Cambrex Corporation U.K.), Carlyle Group (AMRI, U.S.), and others.

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • U.S.
  • Rest of North America
  • Europe
  • Italy
  • Germany
  • France
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Rest of APAC
  • Rest of the World (RoW)
  • Brazil
  • Rest of Latin America
  • Middle East and Others
  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     SCOPE OF THE REPORT
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     INCREASING INCIDENCE AND PREVALENCE OF CHRONIC DISEASES
        • 3.3.1.2     ADOPTION OF BIOLOGICS IN DISEASE MANAGEMENT AND INCREASING REGULATORY APPROVALS IN THE PAST YEAR
        • 3.3.1.3     INCREASING SCOPE OF HPAPI MARKET
        • 3.3.1.4     PATENT EXPIRATION OF MAJOR DRUGS
        • 3.3.1.5     INCREASING TREND OF OUTSOURCING
        • 3.3.1.6     INCREASE IN THE GERIATRIC POPULATION
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     CONTAMINATION OF API
        • 3.3.2.2     HIGH COST FOR MANUFACTURING APIS
        • 3.3.2.3     A REQUIREMENT OF HIGHLY SKILLED TECHNICIANS
        • 3.3.2.4     FIERCE COMPETITION BETWEEN API PLAYERS
        • 3.3.2.5     STRINGENT REGULATORY POLICIES AND ENVIRONMENTAL CONCERNS
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
        • 3.4.1.1     ISO 9001: 2015 QUALITY MANAGEMENT SYSTEM
        • 3.4.1.2     ISO 13408 ASEPTIC PROCESSING
        • 3.4.1.3     ISO 14644-1 CLEAN ROOM STANDARDS
      • 3.4.2     U.S.
      • 3.4.3     CANADA
      • 3.4.4     MEXICO
      • 3.4.5     EUROPE
      • 3.4.6     CHINA
      • 3.4.7     INDIA
      • 3.4.8     JAPAN
      • 3.4.9     AUSTRALIA
      • 3.4.10     SOUTH KOREA
      • 3.4.11     LATIN AMERICA
      • 3.4.12     MIDDLE EAST
    • 3.5     TECHNOLOGICAL ADVANCEMENTS
      • 3.5.1     INTRODUCTION
      • 3.5.2     AUTOMATION AND CONTROL
      • 3.5.3     CONTINUOUS MANUFACTURING
      • 3.5.4     CRYOGENIC TECHNOLOGY
      • 3.5.5     SINGLE - USE SYSTEM (SUS)
      • 3.5.6     MAMMALIAN CELL BASED PRODUCTION
      • 3.5.7     CELL FREE BASED APPROACH FOR THE PRODUCTION OF PROTEINS
      • 3.5.8     ADVANCEMENTS IN HPAPI MANUFACTURING
    • 3.6     PORTER'S FIVE FORCE ANALYSIS
      • 3.6.1     THREAT OF NEW ENTRANTS
      • 3.6.2     THREAT OF SUBSTITUTES
      • 3.6.3     BARGAINING POWER OF SUPPLIERS
      • 3.6.4     BARGAINING POWER OF BUYERS
      • 3.6.5     COMPETITIVE RIVALRY
    • 3.7     SUPPLY CHAIN ANALYSIS
    • 3.8     MARKET SHARE ANALYSIS
    • 3.9     FDA APPROVED API MANUFACTURING UNITS
    • 3.10     PHARMACEUTICAL API PRODUCTION VOLUME
    • 3.11     PATENT EXPIRY AND ANDA APPROVALS
    • 3.12     DRUG MASTER FILING (DMF)
    • 3.13     NOTICE OF INSPECTIONAL OBSERVATIONS (FORM 483)
    • 3.14     REPURPOSED DRUGS FOR COVID-19 TREATMENT
    • 3.15     ACQUISITION, MERGER, AND EXPANSIONS
    • 3.16     COLLABORATION AND AGREEMENT BETWEEN API MANUFACTURERS
    • 3.17     SELECTED TOP SELLING API
    • 3.18     API MANUFACTURERS REVENUE AND CAPABILITIES TABLE
  • 4     API GLOBAL MARKET, BY SYNTHESIS
    • 4.1     INTRODUCTION
    • 4.2     SYNTHETIC API
      • 4.2.1     SYNTHETIC API BY CUSTOMER BASE
        • 4.2.1.1     BRANDED SYNTHETIC API
        • 4.2.1.2     GENERIC SYNTHETIC API
    • 4.3     BIOTECH API
      • 4.3.1     INTRODUCTION
        • 4.3.1.1     MONOCLONAL ANTIBODIES
        • 4.3.1.2     RECOMBINANT PROTEINS
        • 4.3.1.3     VACCINES
        • 4.3.1.4     OTHER BIOTECH API (CELL AND GENE THERAPY)
      • 4.3.2     BIOTECH API BY CUSTOMER BASE
        • 4.3.2.1     BIOLOGIC API
        • 4.3.2.2     BIOSIMILAR API
    • 4.4     HPAPI
      • 4.4.1     HPAPI BY CUSTOMER BASE
        • 4.4.1.1     BRANDED HPAPI
        • 4.4.1.2     GENERIC HPAPI
  • 5     API GLOBAL MARKET, BY BUSINESS TYPE
    • 5.1     INTRODUCTION
    • 5.2     CAPTIVE API BY TYPE
      • 5.2.1     BRANDED CAPTIVE API
      • 5.2.2     GENERIC CAPTIVE API
    • 5.3     MERCHANT API BY TYPE
      • 5.3.1     BRANDED MERCHANT API
      • 5.3.2     GENERIC MERCHANT API
  • 6     API GLOBAL MARKET, BY APPLICATION
    • 6.1     INTRODUCTION
    • 6.2     INFECTIOUS DISEASES
    • 6.3     ONCOLOGY
    • 6.4     CARDIOVASCULAR DISEASES
    • 6.5     CENTRAL NERVOUS SYSTEM
    • 6.6     PULMONARY DISORDERS
    • 6.7     GASTROINTESTINAL DISORDERS
    • 6.8     ENDOCRINE DISORDERS
    • 6.9     METABOLIC DISORDERS
    • 6.10     GENITOURINARY DISORDERS
    • 6.11     MUSCULOSKELETAL DISORDERS
    • 6.12     OTHER APPLICATIONS (ANAESTHASIA, AUTOIMMUNE DISEASES, OPTHALMOLOGY, DENTAL, PAIN MANAGEMENT, GYNAECOLOGY, DERMATOLOGY AND ENT)
  • 7     REGIONAL ANALYSIS
    • 7.1     INTRODUCTION
    • 7.2     NORTH AMERICA
      • 7.2.1     U.S.
      • 7.2.2     REST OF NORTH AMERICA
    • 7.3     EUROPE
      • 7.3.1     ITALY
      • 7.3.2     GERMANY
      • 7.3.3     FRANCE
      • 7.3.4     REST OF EUROPE
    • 7.4     APAC
      • 7.4.1     CHINA
      • 7.4.2     JAPAN
      • 7.4.3     INDIA
      • 7.4.4     REST OF APAC
    • 7.5     ROW
      • 7.5.1     BRAZIL
      • 7.5.2     REST OF LATAM
      • 7.5.3     MIDDLE EAST & OTHERS
  • 8     COMPETITIVE LANDSCAPE
    • 8.1     INTRODUCTION
    • 8.2     PRODUCT APPROVALS
    • 8.3     AGREEMENTS
    • 8.4     EXPANSIONS
    • 8.5     COLLABORATIONS
    • 8.6     PRODUCT LAUNCH
    • 8.7     PARTNERSHIP
    • 8.8     ACQUISITIONS
    • 8.9     OTHERS
  • 9     MAJOR COMPANIES
    • 9.1     CARLYLE GROUP (ALBANY MOLECULAR RESEARCH INC)
      • 9.1.1     OVERVIEW
      • 9.1.2     FINANCIALS
      • 9.1.3     PRODUCT PORTFOLIO
      • 9.1.4     KEY DEVELOPMENTS
      • 9.1.5     BUSINESS STRATEGY
      • 9.1.6     SWOT ANALYSIS
    • 9.2     BOEHRINGER INGELHEIM INTERNATIONAL GMBH
      • 9.2.1     OVERVIEW
      • 9.2.2     FINANCIALS
      • 9.2.3     PRODUCT PORTFOLIO
      • 9.2.4     KEY DEVELOPMENTS
      • 9.2.5     BUSINESS STRATEGY
      • 9.2.6     SWOT ANALYSIS
    • 9.3     DIVIS LABORATORIES
      • 9.3.1     OVERVIEW
      • 9.3.2     FINANCIALS
      • 9.3.3     PRODUCT PORTFOLIO
      • 9.3.4     KEY DEVELOPMENTS
      • 9.3.5     BUSINESS STRATEGY
      • 9.3.6     SWOT ANALYSIS
    • 9.4     LONZA GROUP LTD.
      • 9.4.1     OVERVIEW
      • 9.4.2     FINANCIALS
      • 9.4.3     PRODUCT PORTFOLIO
      • 9.4.4     KEY DEVELOPMENTS
      • 9.4.5     BUSINESS STRATEGY
      • 9.4.6     SWOT ANALYSIS
    • 9.5     OLON S.P.A.
      • 9.5.1     OVERVIEW
      • 9.5.2     FINANCIALS
      • 9.5.3     PRODUCT PORTFOLIO
      • 9.5.4     KEY DEVELOPMENTS
      • 9.5.5     BUSINESS STRATEGY
      • 9.5.6     SWOT ANALYSIS
    • 9.6     PERMIRA FUNDS (CAMBREX CORPORATION U.K.)
      • 9.6.1     OVERVIEW
      • 9.6.2     FINANCIALS
      • 9.6.3     PRODUCT PORTFOLIO
      • 9.6.4     KEY DEVELOPMENTS
      • 9.6.5     BUSINESS STRATEGY
      • 9.6.6     SWOT ANALYSIS
    • 9.7     PFIZER INC.
      • 9.7.1     OVERVIEW
      • 9.7.2     FINANCIALS
      • 9.7.3     PRODUCT PORTFOLIO
      • 9.7.4     KEY DEVELOPMENTS
      • 9.7.5     BUSINESS STRATEGY
      • 9.7.6     SWOT ANALYSIS
    • 9.8     SANOFI
      • 9.8.1     OVERVIEW
      • 9.8.2     FINANCIALS
      • 9.8.3     PRODUCT PORTFOLIO
      • 9.8.4     KEY DEVELOPMENTS
      • 9.8.5     BUSINESS STRATEGY
      • 9.8.6     SWOT ANALYSIS
    • 9.9     TEVA PHARMACEUTICAL INDUSTRIES LIMITED.
      • 9.9.1     OVERVIEW
      • 9.9.2     FINANCIALS
      • 9.9.3     PRODUCT PORTFOLIO
      • 9.9.4     KEY DEVELOPMENTS
      • 9.9.5     BUSINESS STRATEGY
      • 9.9.6     SWOT ANALYSIS
    • 9.10     THERMO FISHER SCIENTIFIC INC
      • 9.10.1     OVERVIEW
      • 9.10.2     FINANCIALS
      • 9.10.3     PRODUCT PORTFOLIO
      • 9.10.4     KEY DEVELOPMENTS
      • 9.10.5     BUSINESS STRATEGY
      • 9.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 2     GLOBAL SMALL MOLECULE API REVENUE ($MN), AVERAGE SELLING PRICE ($/KG) AND PRODUCTION IN TONS, BY APPLICATION (2020)
      • TABLE 3     GLOBAL SMALL MOLECULE VOLUME AND UTILIZATION, CMO VOLUME AND UTILIZATION, (2019-2027) (MILLION LITRES)
      • TABLE 4     GLOBAL SMALL MOLECULE API PRODUCTION, BY APPLICATION, (2019-2027) (TONS)
      • TABLE 5     GLOBAL BIOLOGICS VOLUME AND UTILIZATION, CMO VOLUME AND UTILIZATION, (2019-2027) (MILLION LITRES)
      • TABLE 6     GLOBAL SMALL MOLECULE API PRODUCTION, (2019-2027) (METRIC TONS)
      • TABLE 7     GLOBAL BIOLOGICS API PRODUCTION, (2019-2027) (METRIC TONS)
      • TABLE 8     GLOBAL API PRODUCTION, (2019-2027) (METRIC TONS)
      • TABLE 9     PATENT EXPIRY OF SYNTHETIC API DRUGS, (2017 - 2022)
      • TABLE 10     PATENT EXPIRY OF BIOTECH API DRUGS, (2018 - 2028)
      • TABLE 11     ANDA APPROVALS: SMALL MOLECULES - GENERICS, (2020 - 2021)
      • TABLE 12     ANDA APPROVALS: BIOSIMILARS, (2020)
      • TABLE 13     COMPANIES ACQUISITION AND MERGER, (2018 - 2020)
      • TABLE 14     EXPANSIONS, (2019 - 2021)
      • TABLE 15     COLLABORATIONS AND AGREEMENTS, (2019 - 2021)
      • TABLE 16     API GLOBAL MARKET REVENUE, BY SYNTHESIS, (2019-2027) ($MN)
      • TABLE 17     SYNTHETIC API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 18     SYNTHETIC API GLOBAL MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
      • TABLE 19     BRANDED SYNTHETIC API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 20     GENERIC SYNTHETIC API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 21     BIOTECH API GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 22     BIOTECH API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 23     MONOCLONAL ANTIBODIES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 24     RECOMBINANT PROTEINS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 25     VACCINES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 26     OTHER BIOTECH API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 27     BIOTECH API GLOBAL MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
      • TABLE 28     BIOLOGIC API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 29     BIOSIMILAR API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 30     HPAPI GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 31     HPAPI GLOBAL MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
      • TABLE 32     BRANDED HPAPI GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 33     GENERIC HPAPI GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 34     API GLOBAL MARKET REVENUE, BY BUSINESS TYPE, (2019-2027) ($MN)
      • TABLE 35     CAPTIVE API GLOBAL MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 36     CAPTIVE API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 37     BRANDED CAPTIVE API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 38     GENERIC CAPTIVE API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 39     MERCHANT API GLOBAL MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 40     MERCHANT API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 41     BRANDED MERCHANT API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 42     GENERIC MERCHANT API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 43     API GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 44     SYNTHETIC API GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 45     BIOTECH API GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 46     HPAPI GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 47     INFECTIOUS DISEASES API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 48     SYNTHETIC INFECTIOUS DISEASES API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 49     BIOTECH INFECTIOUS DISEASES API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 50     HPAPI INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 51     ONCOLOGY API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 52     SYNTHETIC ONCOLOGY API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 53     BIOTECH ONCOLOGY API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 54     HPAPI ONCOLOGY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 55     CARDIOVASCULAR DISEASES API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 56     SYNTHETIC CARDIOVASCULAR DISEASES API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 57     BIOTECH CARDIOVASCULAR DISEASES API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 58     HPAPI CARDIOVASCULAR DISEASES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 59     CENTRAL NERVOUS SYSTEM API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 60     SYNTHETIC CENTRAL NERVOUS SYSTEM API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 61     BIOTECH CENTRAL NERVOUS SYSTEM API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 62     HPAPI CENTRAL NERVOUS SYSTEM GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 63     PULMONARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 64     SYNTHETIC PULMONARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 65     BIOTECH PULMONARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 66     HPAPI PULMONARY DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 67     GASTROINTESTINAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 68     SYNTHETIC GASTROINTESTINAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 69     BIOTECH GASTROINTESTINAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 70     GASTROINTESTINAL DISORDERS HPAPI GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 71     ENDOCRINE DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 72     SYNTHETIC ENDOCRINE DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 73     BIOTECH ENDOCRINE DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 74     HPAPI ENDOCRINE DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 75     METABOLIC DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 76     SYNTHETIC METABOLIC DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 77     BIOTECH METABOLIC DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 78     HPAPI METABOLIC DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 79     GENITOURINARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 80     SYNTHETIC GENITOURINARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 81     BIOTECH GENITOURINARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 82     HPAPI GENITOURINARY DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 83     MUSCULOSKELETAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 84     SYNTHETIC MUSCULOSKELETAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 85     BIOTECH MUSCULOSKELETAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 86     HPAPI MUSCULOSKELETAL DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 87     OTHER APPLICATIONS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 88     SYNTHETIC OTHER APPLICATIONS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 89     BIOTECH OTHER APPLICATIONS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 90     HPAPI OTHER APPLICATIONS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 91     API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 92     NORTH AMERICA API MARKET REVENUE, BY SYNTHESIS, (2019-2027) ($MN)
      • TABLE 93     NORTH AMERICA BIOTECH API MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 94     NORTH AMERICA SYNTHETIC API MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
      • TABLE 95     NORTH AMERICA BIOTECH API MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
      • TABLE 96     NORTH AMERICA HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
      • TABLE 97     NORTH AMERICA API MARKET REVENUE, BY BUSINESS TYPE, (2019-2027) ($MN)
      • TABLE 98     NORTH AMERICA CAPTIVE API MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 99     NORTH AMERICA MERCHANT API MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 100     NORTH AMERICA API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 101     NORTH AMERICA SYNTHETIC API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 102     NORTH AMERICA BIOTECH API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 103     NORTH AMERICA HPAPI MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 104     NORTH AMERICA API MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 105     EUROPE API MARKET REVENUE, BY SYNTHESIS, (2019-2027) ($MN)
      • TABLE 106     EUROPE BIOTECH API MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 107     EUROPE SYNTHETIC API MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
      • TABLE 108     EUROPE BIOTECH API MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
      • TABLE 109     EUROPE HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
      • TABLE 110     EUROPE API MARKET REVENUE, BY BUSINESS TYPE, (2019-2027) ($MN)
      • TABLE 111     EUROPE CAPTIVE API MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 112     EUROPE MERCHANT API MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 113     EUROPE API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 114     EUROPE SYNTHETIC API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 115     EUROPE BIOTECH API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 116     EUROPE HPAPI MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 117     EUROPE API MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 118     APAC API MARKET REVENUE, BY SYNTHESIS, (2019-2027) ($MN)
      • TABLE 119     APAC BIOTECH API MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 120     APAC SYNTHETIC API MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
      • TABLE 121     APAC BIOTECH API MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
      • TABLE 122     APAC HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
      • TABLE 123     APAC API MARKET REVENUE, BY BUSINESS TYPE, (2019-2027) ($MN)
      • TABLE 124     APAC CAPTIVE API MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 125     APAC MERCHANT API MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 126     APAC API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 127     APAC SYNTHETIC API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 128     APAC BIOTECH API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 129     APAC HPAPI MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 130     APAC API MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 131     ROW API MARKET REVENUE, BY SYNTHESIS, (2019-2027) ($MN)
      • TABLE 132     ROW BIOTECH API MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 133     ROW SYNTHETIC API MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
      • TABLE 134     ROW BIOTECH API MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
      • TABLE 135     ROW HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
      • TABLE 136     ROW API MARKET REVENUE, BY BUSINESS TYPE, (2019-2027) ($MN)
      • TABLE 137     ROW CAPTIVE API MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 138     ROW MERCHANT API MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 139     ROW API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 140     ROW SYNTHETIC API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 141     ROW BIOTECH API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 142     ROW HPAPI MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 143     ROW API MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 144     PRODUCT APPROVALS
      • TABLE 145     AGREEMENTS
      • TABLE 146     EXPANSIONS
      • TABLE 147     COLLABORATIONS
      • TABLE 148     PRODUCT LAUNCH
      • TABLE 149     PARTNERSHIP
      • TABLE 150     ACQUISITIONS
      • TABLE 151     OTHERS
      • TABLE 152     BOEHRINGER INGELHEIM: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 153     BOEHRINGER INGELHEIM: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 154     BOEHRINGER INGELHEIM: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 155     DIVIS LABORATORIES LTD: TOTAL REVENUE AND R&D EXPENSES (2018-2020) ($MN)
      • TABLE 156     DIVIS LABORATORIES LTD: TOTAL REVENUE, BY GEOGRAPHY (2018-2020) ($MN)
      • TABLE 157     LONZA GROUP: TOTAL REVENUE & R&D EXPENSES (2018 -2020) ($MN)
      • TABLE 158     LONZA GROUP: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
      • TABLE 159     LONZA GROUP: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 160     PFIZER INC: TOTAL REVENUE AND R&D EXPENSES, (2018-2019) ($MN)
      • TABLE 161     PFIZER INC: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 162     PFIZER INC: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 163     SANOFI: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 164     SANOFI: TOTAL REVENUE BY SEGMENT (2018-2020) ($MN)
      • TABLE 165     SANOFI: TOTAL REVENUE BY REGION (2018-2020) ($MN)
      • TABLE 166     TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE AND R&D EXPENSES (2018-2020) ($MN)
      • TABLE 167     TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE BY SEGMENT (2018-2020) ($MN)
      • TABLE 168     TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE BY GEOGRAPHY (2018-2020) ($MN)
      • TABLE 169     THERMO FISHER SCIENTIFIC INC: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 170     THERMO FISHER SCIENTIFIC INC: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
      • TABLE 171     THERMO FISHER SCIENTIFIC INC: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)

      LIST OF FIGURES

      • FIGURE 1     API GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: API GLOBAL MARKET
      • FIGURE 3     API GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     API GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     API GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
      • FIGURE 6     API GLOBAL MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     API GLOBAL MARKET: PORTER'S ANALYSIS
      • FIGURE 9     API GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 10     GLOBAL API MARKET SHARE ANALYSIS, 2020 (%)
      • FIGURE 11     FDA APPROVED GLOBAL API MANUFACTURING LANDSCAPE
      • FIGURE 12     SMALL MOLECULE API PRODUCTION BY APPLICATION (2020), IN-HOUSE V/S CMO (2019 - 2027) (TONS) AND GLOBAL MANUFACTURING CAPACITIES (2020) (LITRES)
      • FIGURE 13     GLOBAL TOTAL API AND CMO PRODUCTION (2019 - 2027) (METRIC TONS)
      • FIGURE 14     PATENT EXPIRY OF SMALL MOLECULES (2017-2022)
      • FIGURE 15     PATENT EXPIRY (2017-2022) AND ANDA APPROVALS (2020 -2021), BY APPLICATION SHARE (%)
      • FIGURE 16     API DMF FILED BY COUNTRIES (2020) (NO'S)
      • FIGURE 17     API DMF FILED, BY COMPANY (2020) (NO'S)
      • FIGURE 18     FORM 483 NON-COMPLIANCE, BY COUNTRY (2020) (NO'S)
      • FIGURE 19     API GLOBAL MARKET SHARE, BY SYNTHESIS, BY CUSTOMER BASE AND BIOTECH API BY PRODUCT TYPE (2020) (%)
      • FIGURE 20     BIOTECH API GLOBAL MARKET SHARE, BY PRODUCT TYPE (2020) (%)
      • FIGURE 21     VACCINES GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 22     GENERIC HPAPI GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 23     API GLOBAL MARKET SHARE, BY BUSINESS TYPE, CAPTIVE API AND MERCHANT API BY TYPE (2020) (%)
      • FIGURE 24     CAPTIVE API GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 25     API GLOBAL MARKET SHARE, BY APPLICATION (2020) (%), CAGR (%)
      • FIGURE 26     SYNTHETIC API GLOBAL MARKET SHARE, BY APPLICATION (2020) (%), CAGR (%)
      • FIGURE 27     BIOTECH API GLOBAL MARKET SHARE, BY APPLICATION, (2020) (%), CAGR (%)
      • FIGURE 28     HPAPI GLOBAL MARKET SHARE, BY APPLICATION, (2020) %, CAGR (%)
      • FIGURE 29     BIOTECH INFECTIOUS DISEASE API GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 30     METABOLIC DISORDER API GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 31     API GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN), CAGR (%)
      • FIGURE 32     API GLOBAL MARKET SHARE, BY REGION AND BY COUNTRY (2020) (%)
      • FIGURE 33     NORTH AMERICA API MARKET SHARE, BY SYNTHESIS AND BIOTECH API MARKET, BY PRODUCT TYPE (2020) (%)
      • FIGURE 34     NORTH AMERICA SYNTHETIC API, BIOTECH API AND HPAPI MARKET SHARE, BY CUSTOMER BASE (2020 V/S 2027) (%)
      • FIGURE 35     NORTH AMERICA API MARKET SHARE, BY BUSINESS TYPE, CAPTIVE API AND MERCHANT API MARKET, BY TYPE (2020 V/S 2027) (%)
      • FIGURE 36     NORTH AMERICA API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 37     NORTH AMERICA SYNTHETIC API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 38     NORTH AMERICA BIOTECH API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 39     NORTH AMERICA HPAPI MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 40     NORTH AMERICA API MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
      • FIGURE 41     U.S. API MARKET REVENUE, BY SYNTHESIS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
      • FIGURE 42     U.S. API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 43     U.S. SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 44     U.S. BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 45     U.S. HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 46     REST OF N.A. API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
      • FIGURE 47     REST OF N.A. API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 48     REST OF N.A. SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 49     REST OF N.A. BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 50     REST OF N.A. HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 51     EUROPE API MARKET SHARE, BY SYNTHESIS AND BIOTECH API MARKET, BY PRODUCT TYPE (2020) (%)
      • FIGURE 52     EUROPE SYNTHETIC API, BIOTECH API AND HPAPI MARKET SHARE, BY CUSTOMER BASE (2020 V/S 2027) (%)
      • FIGURE 53     EUROPE API MARKET SHARE, BY BUSINESS TYPE, CAPTIVE API AND MERCHANT API MARKET, BY TYPE (2020 V/S 2027) (%)
      • FIGURE 54     EUROPE API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 55     EUROPE SYNTHETIC API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 56     EUROPE BIOTECH API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 57     EUROPE HPAPI MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 58     EUROPE API MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
      • FIGURE 59     ITALY API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
      • FIGURE 60     ITALY API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 61     ITALY SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 62     ITALY BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 63     ITALY HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 64     GERMANY API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
      • FIGURE 65     GERMANY API MARKET REVENUE, BY APPLICATION (2020V/S 2027) ($MN)
      • FIGURE 66     GERMANY SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 67     GERMANY BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 68     GERMANY HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 69     FRANCE API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
      • FIGURE 70     FRANCE API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 71     FRANCE SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 72     FRANCE BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 73     FRANCE HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 74     REST OF EUROPE API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
      • FIGURE 75     REST OF EUROPE API MARKET REVENUE, BY APPLICATION (2020 V/S 202) ($MN)
      • FIGURE 76     REST OF EUROPE SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 77     REST OF EUROPE BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 78     REST OF EUROPE HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 79     APAC API MARKET SHARE, BY SYNTHESIS AND BIOTECH API MARKET, BY PRODUCT TYPE (2020 V/S 2027) (%)
      • FIGURE 80     APAC SYNTHETIC API, BIOTECH API AND HPAPI MARKET SHARE, BY CUSTOMER BASE (2020 V/S 2027) (%)
      • FIGURE 81     APAC API MARKET SHARE, BY BUSINESS TYPE, CAPTIVE API AND MERCHANT API MARKET, BY TYPE (2020 V/S 2027) (%)
      • FIGURE 82     APAC API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 83     APAC SYNTHETIC API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 84     APAC BIOTECH API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 85     APAC HPAPI MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 86     REST OF APAC API MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
      • FIGURE 87     CHINA API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
      • FIGURE 88     CHINA API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 89     CHINA SYNTHETIC API MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 90     CHINA BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 91     CHINA HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 92     JAPAN API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
      • FIGURE 93     JAPAN API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 94     JAPAN SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 95     JAPAN BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 96     JAPAN HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 97     INDIA API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
      • FIGURE 98     INDIA API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 99     INDIA SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 100     INDIA BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 101     INDIA HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 102     REST OF APAC API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
      • FIGURE 103     REST OF APAC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 104     REST OF APAC SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 105     REST OF APAC BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 106     REST OF APAC HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 107     ROW API MARKET SHARE, BY SYNTHESIS AND BIOTECH API MARKET, BY TYPE (2020 V/S 2027) (%)
      • FIGURE 108     ROW SYNTHETIC API, BIOTECH API AND HPAPI MARKET SHARE, BY CUSTOMER BASE (2020 V/S 2027) (%)
      • FIGURE 109     ROW API MARKET SHARE, BY BUSINESS TYPE, CAPTIVE API AND MERCHANT API MARKET, BY TYPE (2020 V/S 2027) (%)
      • FIGURE 110     ROW API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 111     ROW SYNTHETIC API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 112     ROW BIOTECH API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 113     ROW HPAPI MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 114     ROW API SHARE, BY COUNTRY (2020 V/S 2027) (%)
      • FIGURE 115     BRAZIL API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
      • FIGURE 116     BRAZIL API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 117     BRAZIL SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 118     BRAZIL BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 119     BRAZIL HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 120     REST OF LATAM API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
      • FIGURE 121     REST OF LATAM API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 122     REST OF LATAM SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 123     REST OF LATAM BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 124     REST OF LATAM HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 125     MIDDLE EAST & OTHERS API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
      • FIGURE 126     MIDDLE EAST & OTHERS API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 127     MIDDLE EAST & OTHERS SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 128     MIDDLE EAST & OTHERS BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 129     MIDDLE EAST & OTHERS HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 130     KEY GROWTH STRATEGIES, (2019-2021)
      • FIGURE 131     SWOT: ALBANY MOLECULAR RESEARCH INC
      • FIGURE 132     SWOT: BOEHRINGER INGELHEIM GMBH
      • FIGURE 133     SWOT: DIVIS LABORATORIES
      • FIGURE 134     SWOT: LONZA GROUP
      • FIGURE 135     SWOT: OLON S.P.A
      • FIGURE 136     SWOT: CAMBREX CORPORATION
      • FIGURE 137     SWOT: PFIZER INC.
      • FIGURE 138     SWOT: SANOFI
      • FIGURE 139     SWOT: TEVA PHARMACEUTICAL INDUSTRIES LIMITED
      • FIGURE 140     SWOT: THERMO FISHER SCIENTIFIC

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     Aarti Drugs Ltd.
      • 2     AbbVie Inc.
      • 3     AbCellera Biologics Inc.
      • 4     Abclonal Inc.
      • 5     Acadia Pharmaceuticals Inc.
      • 6     Aceto
      • 7     ACIC Pharmaceuticals Inc.
      • 8     Adimmune corporation
      • 9     Advance Pharmaceuticals, LLC
      • 10     Aileron Therapeutics Inc.
      • 11     Ajanta Pharma Limited
      • 12     Ajinomoto Bio-Pharma
      • 13     Albemarle Corporation
      • 14     Alcami Corporation, Inc.
      • 15     Alembic Pharmaceuticals Ltd.
      • 16     Alkem Laboratories Ltd.
      • 17     Alkermes Plc
      • 18     Almac group
      • 19     Almelo Private Limited
      • 20     Alpic Remedies Ltd.
      • 21     Alven Laboratories
      • 22     Ambio Pharma Inc.
      • 23     Amega Biotech S.A.
      • 24     Amgen Inc.
      • 25     Amneal Pharmaceuticals LLC
      • 26     Amoytop Biotech
      • 27     Angelini Holding S.p.A.
      • 28     Aprogen
      • 29     Aputit LLC
      • 30     Aravive Inc.
      • 31     Arena Pharmaceuticals, Inc.
      • 32     Arevipharma GmbH
      • 33     Artesan Pharma GmbH & Co. KG
      • 34     Aspire Lifesciences Pvt., Ltd.
      • 35     Astellas Pharma Inc.
      • 36     AstraZeneca plc
      • 37     Aurinia Pharmaceuticals Inc.
      • 38     Aurobindo Pharma Ltd.
      • 39     Avrobio Inc.
      • 40     AZAD Pharmaceutical Ingredients AG
      • 41     Bachem holding AG
      • 42     Bal Pharma Ltd.
      • 43     BASF SE
      • 44     Baxter International Inc.
      • 45     Bayer AG
      • 46     Bio Elpida
      • 47     Bio Genomics Ltd.
      • 48     Bio Marin Pharmaceuticals Inc.
      • 49     Biocin Healthcare
      • 50     Biocon Ltd.
      • 51     Biogen Inc.
      • 52     BioNTech SE
      • 53     Biophore India pharmaceuticals Pvt Ltd
      • 54     Biosint S.p.A.
      • 55     Biotechnica Pharma Global
      • 56     Biovian
      • 57     Blanver Farmoquimica
      • 58     Boehringer Ingelheim GmbH
      • 59     Brammer bio
      • 60     Brawn Biotech Ltd.
      • 61     Bright Path laboratories
      • 62     Bristol-Meyers Squibb
      • 63     Cadila Pharmaceuticals Ltd.
      • 64     Carlyle Group (AMRI)
      • 65     Catalent Inc.
      • 66     Cayman chemical
      • 67     Celltrion Healthcare
      • 68     Century Pharmaceuticals Ltd.
      • 69     Cerbios - pharma S.A.
      • 70     CFM Group (AMSA S.P.A)
      • 71     Changzhou Pharmaceutical Factory
      • 72     ChemCon GmbH
      • 73     China Chemical & Pharmaceutical Co., Ltd.
      • 74     Chongqing Huapont Pharmaceutical Co., Ltd.
      • 75     Cipla Limited
      • 76     CKD Bio
      • 77     Coba pharma S.L.U
      • 78     Corden Pharma International GmbH
      • 79     Cosmo Pharmaceuticals
      • 80     CTX Life Sciences Pvt. Ltd.
      • 81     Daiichi Sankyo Company, Limited
      • 82     Daito Pharmaceutical Co., Ltd.
      • 83     Dalton Pharma Services
      • 84     DCS Pharma AG
      • 85     Delpharm SAS
      • 86     Dishman Carbogen Amcis Limited
      • 87     Divis laboratories Ltd.
      • 88     Dr. Reddy's Laboratories Ltd.
      • 89     Eisai Co., Ltd.
      • 90     Eli Lilly and Company
      • 91     Elusys Therapeutic, Inc.
      • 92     Emcure Pharmaceuticals Ltd.
      • 93     Enaltec Labs Private Limited.
      • 94     Eprius Biopharmaceuticals Inc.
      • 95     Ercros S.A
      • 96     Estechpharma Co., Ltd.
      • 97     Esteve Química
      • 98     Everest Organics Limited
      • 99     Evonik Industries AG (Evonic healthcare)
      • 100     F. Hoffmann-La Roche Ltd
      • 101     Fabbrica Italiana Sintetici S.p.A.
      • 102     Fareva S.A
      • 103     Farmabios SpA
      • 104     Farmhispania Group
      • 105     Ferrer group (Interquim, S.A.)
      • 106     Ferring Pharmaceuticals
      • 107     Flamma S.p.A.
      • 108     Florentis Pharmaceuticals Pvt., Ltd.
      • 109     Formosa Laboratories Inc.
      • 110     Fresenius SE & co. Kgaa
      • 111     Fujifilm Corporation
      • 112     Generex Biotechnology Corperation
      • 113     Gentec Pharmaceutical Group S.A
      • 114     Gilead Sciences, Inc.
      • 115     GlaxoSmithKline plc
      • 116     Glenmark Generics Ltd.
      • 117     Gnosis S.p.A.
      • 118     Granules India Ltd.
      • 119     GVK Industries Limited (GVK Bioscience)
      • 120     Haoyuan Chemexpress Co.Ltd.
      • 121     Harbour BioMed
      • 122     Harman Finochem Limited
      • 123     Heni Chemical Industries
      • 124     Heraues Holding GmbH
      • 125     Hetero Labs Ltd.
      • 126     Honour Lab Ltd.
      • 127     Hovione
      • 128     Huvapharma
      • 129     Hybio Pharmaceutical Co., Ltd.
      • 130     iBio Inc
      • 131     Icrom SpA
      • 132     Inabata France S.A.S.
      • 133     Inalco S.p.A.
      • 134     Indena S.p.A
      • 135     Inpellis Inc.
      • 136     Intas Pharmaceuticals Ltd.
      • 137     Jeil Pharmaceutical Co. Ltd.
      • 138     Johnson & Johnson
      • 139     Jubilant Life Sciences
      • 140     Katsura Chemical Co.,Ltd.
      • 141     KBI Biopharma, Inc.
      • 142     Kern Pharma, S.L.
      • 143     Kleos pharma
      • 144     Kongo Yakuhin Co., Ltd.
      • 145     Kosher Pharmaceuticals
      • 146     KYORIN Holdings, Inc. (KYORIN Pharmaceutical Co., Ltd.)
      • 147     Lannett Co. Inc.
      • 148     Laurus Labs.
      • 149     Lebsa
      • 150     LGM Pharma
      • 151     Libbs Farmacêutica
      • 152     Liptis Pharmaceuticals USA Inc.
      • 153     Lonza Group
      • 154     Lotus Pharmaceutical Co., Ltd.
      • 155     Lupin Limited
      • 156     Lusochimica S.p.A
      • 157     Macleods pharmaceutical Ltd.
      • 158     Magle Chemoswed AB
      • 159     Mallinckrodt Pharmaceuticals
      • 160     Medichem S.A
      • 161     Megafine Pharma Ltd
      • 162     Mehta API
      • 163     Merck KGaA
      • 164     Metrochem API
      • 165     Micro Labs Ltd.
      • 166     Minakem S.A
      • 167     Moehs Iberica S.L.
      • 168     Molcan Corporation
      • 169     Morepen Laboratories Ltd.
      • 170     MSN Laboratories Pvt.Ltd.
      • 171     MViyeS Pharma Ventures Private Limited
      • 172     Natco Pharma Ltd.
      • 173     Neovacs
      • 174     Neuland Laboratories Ltd
      • 175     Neuraxpharm Arzneimittel GmbH
      • 176     Nifty Labs Pvt Ltd.
      • 177     Norchim SAS
      • 178     Novartis International AG
      • 179     Novasep Hodlings SAS
      • 180     Novo Nordisk A/S
      • 181     Novocap S.A.
      • 182     Nuclius Lifesciences
      • 183     Ofichem B.V.
      • 184     Olainfarm AS
      • 185     Olon S.p.A
      • 186     Optimus Pharma Private Ltd.
      • 187     Optum, Inc.
      • 188     Orgenesis Inc.
      • 189     Orion Oy (Fermion Oy)
      • 190     Outlook Therapeutics, Inc.
      • 191     Paratek pharmaceuticals Inc.
      • 192     Permira funds (Cambrex Corporation)
      • 193     Perrigo Company plc
      • 194     Personalized Stem Cells, Inc.
      • 195     Pfanstiehl Inc.
      • 196     Pfizer Inc.
      • 197     Pharmaceutical International Inc.
      • 198     PharmaZell Group
      • 199     Phyton Biotech LLC
      • 200     Pierre Fabre Group
      • 201     Piramal Pharma Solutions
      • 202     Polpharma B2B
      • 203     Prajna Generics Pvt. Ltd.
      • 204     Precise Group
      • 205     Precision BioSciences, Inc.
      • 206     Princeton Biomolecular Research Inc
      • 207     ProBiogen AG
      • 208     Prozomix Limited
      • 209     Raks Pharma Pvt Ltd.
      • 210     Recipharm AB
      • 211     Regeneron Pharmaceuticals, Inc.
      • 212     Reine Lifescience
      • 213     Reva Pharma Pvt., Ltd.
      • 214     Rinque pharma S.A
      • 215     Rochem International Inc.
      • 216     RPG Life Sciences Ltd.
      • 217     Rxn Chemicals Pvt. Ltd.
      • 218     Saamya Biotech (India) Ltd.
      • 219     Sajjala Bio Labs
      • 220     Samsung Biologics Co. Ltd.
      • 221     Saneca Pharmaceuticals a.s.
      • 222     Sanofi S.A.
      • 223     ScinoPharm Taiwan Ltd.
      • 224     Seattle Genetics Inc.
      • 225     Seqens Group
      • 226     Serenity Pharmaceuticals Corp
      • 227     Sermonix Pharmaceuticals
      • 228     Shanghai Fosun Pharmaceutical（Group）Co., Ltd.
      • 229     Shanghai Henlius Biotech, Inc.
      • 230     Shenzhen Haorui Industrial Dev.
      • 231     Shilpa Medicare Limited
      • 232     Shiono Chemical Co., Ltd.
      • 233     Shionogi & Co. Ltd.
      • 234     Shreeji Pharma International
      • 235     Sichuan Clover Biopharmaceuticals, Inc.
      • 236     Siegfried Holdinngs AG
      • 237     SM Biomed SDN. BHD
      • 238     Smilax Laboratories Limited
      • 239     SMS Pharmaceuticals Limited
      • 240     Spark therapeutics
      • 241     Srini Pharmaceuticals Ltd.
      • 242     STADA Arzneimittel AG
      • 243     Standard Chemical & Pharmaceutical Co.
      • 244     Sterling Biotech Ltd.
      • 245     Sumitomo Dainippon Pharma Co., Ltd.
      • 246     Sun Pharmaceutical Industries Ltd.
      • 247     Suven Life Science Ltd
      • 248     Suzhou Ryway Biotech
      • 249     Symbiotec Pharma lab Pvt., Ltd
      • 250     Synergene Active Ingredients Pvt, Ltd.
      • 251     Syn-tech chem. And Pharma.Co., Ltd.
      • 252     Takeda Pharmaceutical Company Ltd.
      • 253     Taro Pharmaceutical Industries Ltd.
      • 254     TB Alliance
      • 255     Temad Co.
      • 256     Tetraphase Pharmaceutical Inc.
      • 257     Teva Pharmaceutical Industries Ltd
      • 258     TherapeuticMd Inc.
      • 259     Theravance biopharma, Inc.
      • 260     Thermo Fisher Scientific
      • 261     TiGenix NV
      • 262     Tonix Pharmaceuticals
      • 263     Torrent Pharmaceuticals, Ltd.
      • 264     trenzyme GmbH
      • 265     Trimax Bio Sciences (P) Limited
      • 266     Umicore N.V.
      • 267     Unichem Laboratories Ltd.
      • 268     Union Quimico Farmaceutica, S.A.
      • 269     Unique Biotech Ltd.
      • 270     USV Private Ltd.
      • 271     Vaishali Pharma Ltd.
      • 272     Vertex Pharmaceuticals
      • 273     Viatris Inc. (Mylan N.V./Upjohn Pfizer Inc.)
      • 274     Vir Biotechnology, Inc.
      • 275     Viruj Pharmaceuticals Pvt, Ltd.
      • 276     Vivimed labs Ltd.
      • 277     Wanbury Ltd.
      • 278     Wavelength Pharmaceuticals
      • 279     Welt Care Lifesciences Pvt., Ltd.
      • 280     Wockhardt
      • 281     WuXi AppTec (STA Pharmaceutical Co., Ltd.)
      • 282     WuXi Biologics
      • 283     Xellia Pharmaceuticals
      • 284     Xiamen Amoytop Biotech Co., Ltd.
      • 285     Yabao Pharmaceutical Group Co., Ltd.
      • 286     Yung Zip Chemical Industrial Co., Ltd.
      • 287     Zambon group (Zach)
      • 288     Zcl Chemicals Ltd.
      • 289     Zhejiang Huahai Pharmaceutical Co., Ltd.
      • 290     Zydus Cadila